Pemetrexed 500

Pemetrexed 500 mg Injection
Pemetrexed 500 mg Injection is a multitargeted antifolate antineoplastic agent used primarily in the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It inhibits key folate-dependent enzymes required for DNA and RNA synthesis, thereby preventing cancer cell replication. Pemetrexed is widely used in combination and maintenance chemotherapy regimens.
Product Details
Generic Name: Pemetrexed (as Pemetrexed Disodium)
Strength: 500 mg
Dosage Form: Injection (Sterile lyophilized powder for reconstitution)
Route of Administration: Intravenous (IV infusion)
Therapeutic Class: Antifolate Anticancer Agent
Indications
Pemetrexed 500 mg Injection is indicated for the treatment of:
Non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
Maintenance therapy in advanced lung cancer (as prescribed)
Mechanism of Action
Pemetrexed inhibits multiple folate-dependent enzymes, including thymidylate synthase and dihydrofolate reductase, disrupting DNA and RNA synthesis and leading to cancer cell death.
Key Benefits
Multitargeted antifolate action
Proven efficacy in lung cancer and mesothelioma
Suitable for combination and maintenance therapy
Widely accepted in global oncology treatment protocols
Dosage & Administration
Dosage and infusion schedule are determined by the oncologist based on body surface area (BSA), indication, and patient condition. Administration should be carried out only under strict medical supervision.
Storage Conditions
Store below 25°C
Protect from light
Do not freeze
Precautions
For hospital and oncology clinic use only
Folic acid and vitamin B12 supplementation is recommended
Regular monitoring of blood counts and renal function is advised
Use with caution in patients with renal impairment